title: Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance.
abstract: BACKGROUND
  A new diagnostic and prognostic biomarker may be of value in cancer diseases. Our study aimed to evaluate the CDKN1A/p21 and TGFBR2 level measurable in a cohort of patients with breast cancer after mastectomy, and to confirm their suitability to serve as prognostic biomarkers of the cancer.
  
  
  METHODS
  The expression levels of CDKN1A/p21 and TGFBR2 were detected by reverse transcription-PCR (RT-PCR), western blot assay and immunohistochemical staining for 65 primary tumor samples and paired adjacent noncancerous breast tissues. Their relations to clinicopathologic parameters and to the prognosis of patients with breast cancer were analyzed.
  
  
  RESULTS
  We found the mRNA and protein expression levels of CDKN1A/p21 were significantly upregulated in breast cancer tissues compared with adjacent nontumorous breast tissues. Increased CDKN1A/p21 expression showed a significant correlation with larger tumor size (P=0.014), higher tumor dedifferentiation grade (P=0.021), lymph node metastasis (P=0.019) and a shorter disease-free survival (P=0.044). Contrarily, the expression levels of TGFBR2 mRNA and protein were significantly decreased in breast cancer tissues compared with adjacent nontumorous breast tissues. Underexpression of TGFBR2 in breast cancer was correlated with larger tumor size (P=0.034), lymph node metastasis (P=0.039) and a shorter disease-free survival (P=0.035). Statistical analysis suggested that there was no significant association between CDKN1A/p21 and TGFBR2 expression.
  
  
  CONCLUSIONS
  in summary, our results suggested that high CDKN1A/p21 and low TGFBR2 expression was closely correlated with adverse pathological parameters and poor prognosis in breast cancer. Both CDKN1A/p21 and TGFBR2 are presented as possible candidates for breast cancer biomarkers.
authors.affiliation: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Chang-Yuan
authors.initials: CY
authors.lastname: Wei
authors.affiliation: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Qi-Xing
authors.initials: QX
authors.lastname: Tan
authors.affiliation: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Qing-Hong
authors.initials: QH
authors.lastname: Qin
authors.affiliation: Department of Obstetrics and Gynecology, Wenzhou Central Hospital Wenzhou 325000, China.
authors.forename: Fei-Bai
authors.initials: FB
authors.lastname: Zhu
authors.affiliation: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Qin-Guo
authors.initials: QG
authors.lastname: Mo
authors.affiliation: Department of Ultrasound Diagnosis, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, China.
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000032:analysis / Q000096:biosynthesis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D017346:Protein Serine-Threonine Kinases / Q000032:analysis / Q000096:biosynthesis*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000032:analysis / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II
keywords: CDKN1A/p21; TGFBR2; biomarker; breast cancer
references.citation: J Cell Biochem. 2011 Dec;112(12):3502-6
references.pmid: 21815189
references.citation: Dis Esophagus. 2012 Jan;25(1):67-71
references.pmid: 21689205
references.citation: Cancer Biomark. 2012;11(5):209-17
references.pmid: 23220853
references.citation: Cancer Genomics Proteomics. 2013 Jan-Feb;10(1):27-34
references.pmid: 23382584
references.citation: Steroids. 2013 Jun;78(6):559-67
references.pmid: 23178160
references.citation: Cancer Lett. 2013 Oct 28;340(1):22-9
references.pmid: 23811286
references.citation: Anticancer Res. 2013 Oct;33(10):4329-35
references.pmid: 24123000
references.citation: J Surg Oncol. 2014 Jun;109(8):859-64
references.pmid: 24619835
references.citation: Breast Cancer Res. 2012;14(5):R127
references.pmid: 22995475
references.citation: BMC Cancer. 2014;14:650
references.pmid: 25182632
references.citation: Clin Cancer Res. 2004 Jan 15;10(2):491-8
references.pmid: 14760070
references.citation: Cell Cycle. 2004 May;3(5):597-600
references.pmid: 15107620
references.citation: J Biol Chem. 2004 Jun 4;279(23):24505-13
references.pmid: 15044465
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3815-24
references.pmid: 15173090
references.citation: Nature. 1993 Dec 16;366(6456):701-4
references.pmid: 8259214
references.citation: Clin Cancer Res. 1996 Sep;2(9):1591-9
references.pmid: 9816338
references.citation: Biochim Biophys Acta. 2005 Mar 22;1743(1-2):151-61
references.pmid: 15777850
references.citation: Nat Rev Cancer. 2006 Jul;6(7):506-20
references.pmid: 16794634
references.citation: Br J Cancer. 2007 Feb 26;96(4):639-45
references.pmid: 17285125
references.citation: Anticancer Res. 2007 May-Jun;27(3B):1679-84
references.pmid: 17595796
references.citation: Cell. 2008 Jul 25;134(2):215-30
references.pmid: 18662538
references.citation: Cell Res. 2009 Jan;19(1):89-102
references.pmid: 19050696
references.citation: Mol Cancer Res. 2009 Apr;7(4):592-600
references.pmid: 19372587
references.citation: Nat Rev Cancer. 2009 Jun;9(6):400-14
references.pmid: 19440234
references.citation: Biochim Biophys Acta. 2009 Jul;1793(7):1165-73
references.pmid: 19339207
references.citation: Front Biosci (Landmark Ed). 2010;15:180-94
references.pmid: 20036814
references.citation: Ann Oncol. 2010 Apr;21(4):734-40
references.pmid: 19914962
references.citation: Breast Cancer Res Treat. 2010 Jun;121(3):727-35
references.pmid: 19937272
references.citation: World J Gastroenterol. 2010 Oct 21;16(39):4958-67
references.pmid: 20954283
references.citation: Biochem Biophys Res Commun. 2010 Dec 3;403(1):103-7
references.pmid: 21040707
references.citation: Oncol Rep. 2014 Dec;32(6):2517-26
references.pmid: 25333671
references.citation: Oncogene. 2015 Jan 2;34(1):27-38
references.pmid: 24336330
references.citation: Breast Cancer Res. 2014;16(5):425
references.pmid: 25280532
references.citation: Nat Rev Cancer. 2010 Jun;10(6):415-24
references.pmid: 20495575
references.citation: Histopathology. 2000 Feb;36(2):168-77
references.pmid: 10672063
references.citation: Mol Cell Biol. 2001 Aug;21(16):5644-57
references.pmid: 11463845
references.citation: Virchows Arch. 2001 Aug;439(2):132-40
references.pmid: 11561753
references.citation: Breast Cancer Res. 2003;5(6):R242-9
references.pmid: 14580260